JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Raynaud, F. I.
Right arrow Articles by Cotter, F. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raynaud, F. I.
Right arrow Articles by Cotter, F. E.

Vol. 281, Issue 1, 420-427, 1997

Pharmacokinetics of G3139, a Phosphorothioate Oligodeoxynucleotide Antisense to bcl-2, after Intravenous Administration or Continuous Subcutaneous Infusion to Mice1

Florence I. Raynaud, Rosanne M. Orr, Phyllis M. Goddard, Heidi A. Lacey, Helen Lancashire, Ian R. Judson, Terry Beck, Bob Bryan and Finbarr E. Cotter

Cancer Research Campaign Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom (F.I.R., R.M.O., P.M.G., H.Lac., H.Lan., I.R.J.), Genta Inc., San Diego, California (T.B., B.B.), and Leukaemia Research Fund, Institute of Child Health, London, United Kingdom (F.E.C.)

An 18-mer full-phosphorothioate oligonucleotide with sequence antisense to the first six codons of the open reading frame of bcl-2 (G3139) has shown efficacy against the DoHH2 lymphoma implanted in severe combined immunodeficient mice. This study evaluated the pharmacokinetics of 35S-labeled G3139 in female BALB/c mice after single i.v. bolus administration or s.c. infusion for 1 week. After 100 µg i.v. bolus (approximately 5 mg/kg), the radioactivity was rapidly distributed and eliminated, with low blood levels 6 hr after administration. Most of the initial plasma radioactivity was protein bound (98% at 5 min). Tissue to plasma ratios were 87 for kidney, 17 for liver, 5 for spleen, 2.5 for heart and lung and 3.5 for gut. High-performance liquid chromatographic determination of G3139 showed triexponential kinetics, with alpha , beta  and gamma  half-lives of 5 min, 37 min and 11 hr, respectively. After 106 µg/day s.c. infusion, plasma steady state was reached by day 3, when half of the radioactivity was protein bound and 66 to 86% of the radioactivity was associated with parent drug (0.9 µg/ml). The plasma half-life of elimination for G3139 was 22 hr. Tissue to plasma ratios were similar to those after i.v. bolus administration, but accumulation was observed in all organs including bone marrow, where the levels reached were in the cytotoxic range. G3139 was metabolized to at least three different products, all observed in plasma, liver and kidney. Two metabolites eluted before the parent compound and one after the parent compound. There was greater degradation in the liver 6 hr after i.v. administration than at 24 hr, 48 hr, 3 days and 7 days after s.c. administration. In the kidney, most radioactivity was G3139. All degradation products were found in the urine but only traces of parent drug were eliminated. After both routes of administration, most of the radioactivity was eliminated in the urine and to a lesser extent in the feces. Significantly more radioactivity was excreted in the urine after i.v. bolus, compared with s.c. infusion (33% on day 1 and 55% by day 3 for i.v. vs. 7.2% on day 1 and 12.9% by day 3 for s.c.). These data show that s.c. infusion resulted in less excretion and metabolism of the administered dose.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
O. A. O'Connor, E. A. Smith, L. E. Toner, J. Teruya-Feldstein, S. Frankel, M. Rolfe, X. Wei, S. Liu, G. Marcucci, K. K. Chan, et al.
The Combination of the Proteasome Inhibitor Bortezomib and the Bcl-2 Antisense Molecule Oblimersen Sensitizes Human B-Cell Lymphomas to Cyclophosphamide.
Clin. Cancer Res., May 1, 2006; 12(9): 2902 - 2911.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. M. Levine, A. Tulpule, D. I. Quinn, G. Gorospe III, D. L. Smith, L. Hornor, W. D. Boswell, B. M. Espina, S. G. Groshen, R. Masood, et al.
Phase I Study of Antisense Oligonucleotide Against Vascular Endothelial Growth Factor: Decrease in Plasma Vascular Endothelial Growth Factor With Potential Clinical Efficacy
J. Clin. Oncol., April 10, 2006; 24(11): 1712 - 1719.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. M. Mita, L. Ochoa, E. K. Rowinsky, J. Kuhn, G. Schwartz, L. A. Hammond, A. Patnaik, I.-T. Yeh, E. Izbicka, K. Berg, et al.
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (GenasenseTM, G3139) and irinotecan in patients with metastatic colorectal cancer
Ann. Onc., February 1, 2006; 17(2): 313 - 321.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. M. O'Brien, C. C. Cunningham, A. K. Golenkov, A. G. Turkina, S. C. Novick, and K. R. Rai
Phase I to II Multicenter Study of Oblimersen Sodium, a Bcl-2 Antisense Oligonucleotide, in Patients With Advanced Chronic Lymphocytic Leukemia
J. Clin. Oncol., October 20, 2005; 23(30): 7697 - 7702.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Z. Badros, O. Goloubeva, A. P. Rapoport, B. Ratterree, N. Gahres, B. Meisenberg, N. Takebe, M. Heyman, J. Zwiebel, H. Streicher, et al.
Phase II Study of G3139, a Bcl-2 Antisense Oligonucleotide, in Combination With Dexamethasone and Thalidomide in Relapsed Multiple Myeloma Patients
J. Clin. Oncol., June 20, 2005; 23(18): 4089 - 4099.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Dai, K. K. Chan, S. Liu, D. Hoyt, S. Whitman, M. Klisovic, T. Shen, M. A. Caligiuri, J. Byrd, M. Grever, et al.
Cellular Uptake and Intracellular Levels of the Bcl-2 Antisense G3139 in Cultured Cells and Treated Patients with Acute Myeloid Leukemia
Clin. Cancer Res., April 15, 2005; 11(8): 2998 - 3008.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Yano, K. Hirabayashi, S.-i. Nakagawa, T. Yamaguchi, M. Nogawa, I. Kashimori, H. Naito, H. Kitagawa, K. Ishiyama, T. Ohgi, et al.
Antitumor Activity of Small Interfering RNA/Cationic Liposome Complex in Mouse Models of Cancer
Clin. Cancer Res., November 15, 2004; 10(22): 7721 - 7726.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Marshall, H. Chen, D. Yang, M. Figueira, K. B. Bouker, Y. Ling, M. Lippman, S. R. Frankel, and D. F. Hayes
A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors
Ann. Onc., August 1, 2004; 15(8): 1274 - 1283.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. M. Rudin, M. Kozloff, P. C. Hoffman, M. J. Edelman, R. Karnauskas, R. Tomek, L. Szeto, and E. E. Vokes
Phase I Study of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Carboplatin and Etoposide in Patients With Small-Cell Lung Cancer
J. Clin. Oncol., March 15, 2004; 22(6): 1110 - 1117.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Tauchi, M. Sumi, A. Nakajima, G. Sashida, T. Shimamoto, and K. Ohyashiki
BCL-2 Antisense Oligonucleotide Genasense Is Active against Imatinib-resistant BCR-ABL-positive Cells
Clin. Cancer Res., September 15, 2003; 9(11): 4267 - 4273.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Q. Liu and Y. Gazitt
Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells
Blood, May 15, 2003; 101(10): 4105 - 4114.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Goodin, K. V. Rao, and R. S. DiPaola
State-of-the-Art Treatment of Metastatic Hormone-Refractory Prostate Cancer
Oncologist, August 1, 2002; 7(4): 360 - 370.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. M. Rudin, G. A. Otterson, A. M. Mauer, M. A. Villalona-Calero, R. Tomek, B. Prange, C. M. George, L. Szeto, and E. E. Vokes
A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer
Ann. Onc., April 1, 2002; 13(4): 539 - 545.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. J. Morris, W. P. Tong, C. Cordon-Cardo, M. Drobnjak, W. K. Kelly, S. F. Slovin, K. L. Terry, K. Siedlecki, P. Swanson, M. Rafi, et al.
Phase I Trial of BCL-2 Antisense Oligonucleotide (G3139) Administered by Continuous Intravenous Infusion in Patients with Advanced Cancer
Clin. Cancer Res., March 1, 2002; 8(3): 679 - 683.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. M. Vose, B. C.-H. Chiu, B. D. Cheson, J. Dancey, and J. Wright
Update on Epidemiology and Therapeutics for Non-Hodgkin's Lymphoma
Hematology, January 1, 2002; 2002(1): 241 - 262.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
K. N. Chi, M. E. Gleave, R. Klasa, N. Murray, C. Bryce, D. E. Lopes de Menezes, S. D'Aloisio, and A. W. Tolcher
A Phase I Dose-finding Study of Combined Treatment with an Antisense Bcl-2 Oligonucleotide (Genasense) and Mitoxantrone in Patients with Metastatic Hormone-refractory Prostate Cancer
Clin. Cancer Res., December 1, 2001; 7(12): 3920 - 3927.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
R. J. Klasa, A. F. List, and B. D. Cheson
Rational Approaches to Design of Therapeutics Targeting Molecular Markers
Hematology, January 1, 2001; 2001(1): 443 - 462.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
L. Q. Sun, M. J. Cairns, E. G. Saravolac, A. Baker, and W. L. Gerlach
Catalytic Nucleic Acids: From Lab to Applications
Pharmacol. Rev., September 1, 2000; 52(3): 325 - 348.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Chen, Y. C. Zhang, D. Li, M. I. Phillips, P. Mehta, M. Shi, and J. L. Mehta
Protection against Myocardial Dysfunction Induced by Global Ischemia-Reperfusion by Antisense-Oligodeoxynucleotides Directed at beta 1-Adrenoceptor mRNA
J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 722 - 727.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
D. E. Lopes de Menezes, N. Hudon, N. McIntosh, and L. D. Mayer
Molecular and Pharmacokinetic Properties Associated with the Therapeutics of Bcl-2 Antisense Oligonucleotide G3139 Combined with Free and Liposomal Doxorubicin
Clin. Cancer Res., July 1, 2000; 6(7): 2891 - 2902.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
R. J. Klasa, M. B. Bally, R. Ng, J. H. Goldie, R. D. Gascoyne, and F. M. P. Wong
Eradication of Human Non-Hodgkin's Lymphoma in SCID Mice by BCL-2 Antisense Oligonucleotides Combined with Low-Dose Cyclophosphamide
Clin. Cancer Res., June 1, 2000; 6(6): 2492 - 2500.
[Abstract] [Full Text]

Home page
 JCOHome page
J. S. Waters, A. Webb, D. Cunningham, P. A. Clarke, F. Raynaud, F. di Stefano, and F. E. Cotter
Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin's Lymphoma
J. Clin. Oncol., May 9, 2000; 18(9): 1812 - 1823.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y. Gutiérrez-Puente, A. M. Tari, C. Stephens, M. Rosenblum, R. T. Guerra, and G. Lopez-Berestein
Safety, Pharmacokinetics, and Tissue Distribution of Liposomal P-Ethoxy Antisense Oligonucleotides Targeted to Bcl-2
J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 865 - 869.
[Abstract] [Full Text]

Home page
 J Oncol Pharm PractHome page
P. J Medina, R. S DiPaola, and S. Goodin
Treatment of hormone-refractory prostate cancer
Journal of Oncology Pharmacy Practice, March 1, 1999; 5(1): 32 - 48.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.